Consensus guidelines for antibacterial prophylaxis in patients with neutropenia
Internal Medicine Journal · 2025-12 · 55 (S7) · 115-135
DOI: 10.1111/imj.70250 ↗Kurz gefasst
Leitlinie in der Zeitschrift Internal Medicine Journal, online erschienen am 11.01.2026. Verfasst von Julian Lindsay und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Antibiotic Prophylaxis, Neutropenia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: the National Institute of Allergy and Infectious Diseases (NIH).
Abstract (Originalsprache)
Since the publication of the Australian consensus guidelines in 2011, the routine use of prophylactic antibiotics in patients with neutropenia has remained controversial, because of concern that the risks of promoting antimicrobial resistance outweighed the level of evidence that their use reduced mortality. Populations at risk have changed over this period and now include a multitude of new cancer therapies, such as targeted cancer therapies and immunotherapies. Emerging understanding about the importance and role of the microbiome in defining treatment response and patterns of antibiotic resistance has also expanded. In addition, the management of neutropenic fever has improved significantly through the development and routine implementation of sepsis pathways. These updated consensus guidelines review recent evidence for the use of antibacterial prophylaxis in adults and children receiving cancer therapies associated with neutropenia. Recommendations presented in these guidelines were based on evaluating current evidence for the benefits and harms of antibacterial prophylaxis while considering the current Australian and New Zealand healthcare setting. In most circumstances, the potential harm of antibiotic resistance, adverse effects of antibiotics and disruption to the microbiome, outweighed the benefit of reducing the incidence of infection, without a benefit in mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Infectious Diseases, Perth Children's Hospital, Perth, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Förderung
- the National Institute of Allergy and Infectious Diseases (NIH)
Zitieren
APA
Lindsay, J., Yeoh, D., Teh, B. W., Reynolds, G. K., Henden, A., McQuilten, Z., Wheeler, M., Hamilton, A., Nelson, A., Nakagaki, M., Sandhu, S., Slavin, M. A., & Australasian Neutropenic Fever Guidelines Steering Committee (2025). Consensus guidelines for antibacterial prophylaxis in patients with neutropenia. Internal Medicine Journal, 55(S7), 115-135. https://doi.org/10.1111/imj.70250
Vancouver
Lindsay J, Yeoh D, Teh BW, Reynolds GK, Henden A, McQuilten Z, et al. Consensus guidelines for antibacterial prophylaxis in patients with neutropenia. Internal Medicine Journal. 2025;55(S7):115-135. doi:10.1111/imj.70250
BibTeX
@article{Lindsay2025,
author = {Lindsay, Julian and Yeoh, Daniel and Teh, Benjamin W and Reynolds, Gemma K and Henden, Andrea and McQuilten, Zoe and Wheeler, Matthew and Hamilton, Anne and Nelson, Adam and Nakagaki, Midori and Sandhu, Shahneen and Slavin, Monica A and Australasian Neutropenic Fever Guidelines Steering Committee, Australasian Neutropenic Fever Guidelines Steering Committee},
title = {Consensus guidelines for antibacterial prophylaxis in patients with neutropenia},
journal = {Internal Medicine Journal},
year = {2025},
volume = {55},
number = {S7},
pages = {115--135},
doi = {10.1111/imj.70250}
}
EUVIMED